Company Overview
Who we are
- Zi Diligence is a leading Pharmaceutical Research Organization established by Dr. Mosaad Morsi in 2014, Egypt, to provide outstanding clinical & bioanalytical services for the pharmaceutical industry in adherence to GCP & GLP principles in accordance with EMA, FDA, ICH and WHO.
- Zi Diligence is the first and only Bioequivalence Center in Egypt to be accredited from GCC, ISO:IEC 17025:2017 and ISO 9001:2015 certified.
- Zi Diligence is Approved by Ministry of Health – Egypt, 2015
- Approved by Gulf Cooperation Council-GCC, 2017
- Certifications; ISO 9001:2015
- Accredited by: ISO / IEC 17025:2017
Mission
Being the most reliable and service oriented Research Center in the pharmaceutical Research, nationally and internationally accredited, with excellent Quality service to the utmost satisfaction of our business associates, while keeping compliance to ethical, regulatory and scientific requirements
Vision
To become one of the most proficient, competitive, and trustworthy Research Center worldwide. Endeavoring to exceed client expectations, achieve benchmark solutions and to be the global leader in Bioequivalence and pharmaceutical research.
The Value We Provide
Integrity
commitment to the highest levels of ethics and respect.
Quality
Stringent quality management systems and strong track record of regulatory inspections and adherence to international standards and regulations
Customer Satisfaction
tailoring our service to clients’ needs exceeding their expectations through flexible solutions. With value-add technical expertise
Innovation
World-class facilities and equipment that remain at the forefront of the global pharmaceutical research, analytical and development standards
Our Team
Dr. Mosaad Morsi dedicated to advancing Pharmaceutical science founded Zi Diligence over 8 years ago.
Today, Zi Diligence is a well-established Pharmaceutical Research organization operating pharmaceutical studies in Egypt. Our team of more than 30 professional multidisciplinary experts works with clients with the same entrepreneurial spirit our founders demonstrated every day.
Our number one objective is to exceed your expectations through teamwork and our enthusiastic attitude.
Our Chairman of Zi Diligence
Dr. Mosaad Morsi
Dr. Mosaad Morsi is a dynamic leader in the pharmaceutical industry in the Middle East; being the Chairman and CEO of the largest pharmaceutical companies in Middle East launching transformative changes in medical and pharmaceutical research services
- Zi-Diligence : Bio-analytical Center
- RAY: Clinical Research Services (RAY-CRO)and Patient Support Services (RAY-PSP)
- Dataclin: Contract Research Organization
- Pharmamed: Medical Translation Services
- Clin-m: Clinical Supplies Management
His primary goal is to promptly and continually improve the overall quality of scientific research and healthcare services, ultimately improving patient outcomes. He remains committed to implementing a patient-centered approach through ethics, quality and compliance.
Inspiring success story
Dr. Mosaad Morsi graduated from faculty of medicine, Cairo University, holds an MSc in Dermatology and Venereology from Al Azhar University and practiced medicine for several years in Egypt, Saudi Arabia and Kuwait.later, He was the medical and regulatory affairs director of Sanofi Egypt for 10 years and also held several leading positions at Pfizer Middle East, including the medical director and clinical research director for 13 years. Furthermore, he was designated as a team leader of a novel medicinal product for Pfizer Africa, Middle East, India and Pakistan.
After joining the industry, he became actively involved in clinical research as well as medical and regulatory fields, and developed a comprehensive understanding of the standards imposed by both local and international regulatory bodies. He received extensive training on ICH/GCP guidelines and clinical research management, and conducted basic and advanced GCP training programs to hundreds of physicians and investigators in the Middle East. Throughout his career, he has successfully managed numerous clinical studies at different phases of drug development by ensuring full compliance with ethics and quality standards.